External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home EHA 2022
Roche and Genentech at

EHA 2022

June 09 - June 12
Vienna, Austria / Virtual (Hybrid)
ehaweb.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
10:15 AM
Duration 5mins Vienna, Austria / Virtual (Hybrid)
Roche-Sponsored DLBCL Symposium at EHA2022: Changing Treatment Paradigms: A New Dawn in DLBCL Treatment Showfile
Ulrich Jager, Franck Morschhauser, Laurie Sehn, Michael Dickinson, Bjorn Chapuy
Haematology | Diffuse Large B-Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 AM
Duration 15mins Hall C1
Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the gallium study
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips E, Dreyling M, Seymour JF, Grigg A, Trotman J,, Lin TY, Hong XN, Klingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R
Haematology - Oncology | Follicular Lymphoma - Relapsed Refractory Non Hodgkin Lymphoma - Non Hodgkin Lymphoma - Leukaemia & Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Hall A8
RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed/refractory multiple myeloma: preliminary results from a first-in-human trial
Riley CH, Hutchings M, Yoon S-S, Koh Y, Manier S, Facon T, Harrison SJ, Er J, Volzone F, Pinto A, Montes Gaisán C, Ocio EM, Alfonso-Pierola A, Rodríguez Otero P, Offner F, Guidetti S, Corradini P, Titouan C, Hulin C, Touzeau C, Moreau P, Popat R, Leong S, Mazza R, Bröske A-M, Dekhtiarenko I, Helms H-J, Belli S, Vardar T, Fauti T, Eckmann J, Moore T, Schneider M, Jacob W, Weisser M, Carlo-Stella C
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 15mins Hall C1
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥2 prior therapies: pivotal Phase II expansion results
Dickinson M, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu S-J, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Clark E, Humphrey K, Martin M
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Hall A8
T-cell activation and myeloma cell killing confirm the mode of action of RG6234, a novel GPRC5D T-cell engaging bispecific antibody, in patients with relapsed/refractory multiple myeloma
Dekhtiarenko I, Lelios I, Attig J, Sleiman N, Lazzaro D, Clausen I, Gräfe N, Helms H-J, Schindler E, Belli S, Fauti T, Eckmann J, Umana P, Jacob W, Schneider M, Riley CH, Hutchings M, Yoon S-S, Koh Y, Manier S, Facon T, Harrison SJ, Er J, Volzone F, Pinto A, Montes Gaisán C, Ocio EM, Alfonso-Pierola A, Rodríguez Otero P, Offner F, Guidetti A, Corradini P, Titouan C, Hulin C, Touzeau C, Moreau P, Popat R, Leong S, Mazza R, Carlo-Stella C, Bröske A-M
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Hall Stolz 1-2
Transcriptomic characterization of MRD response and non-response in pts treated with fixed-duration Venetoclax-Obinutuzumab
Al-Sawaf O, Jin HY, Zhang C, Choi Y, Balasubramanian S, Robrecht S, Kotak A, Chang N, Fink A-M, Tausch E, Schneider C, Ritgen M, Kreuzer K-A, Chyla B, Paulson J, Eichhorst B, Jiang Y, Stilgenbauer S, Jiang Y, Hallek M, Fischer K
Haematology - Oncology | Chronic Lymphocytic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 PM
Duration 5mins Vienna, Austria / Virtual (Hybrid)
Roche-Sponsored FL Symposium at EHA 2022: T-cell Engaging Bispecific Atibodies: A New Era in the Management of Relapsed/Refractory Follicular Lymphoma Showfile
Wendy Osborne, Emmanuel Bachy, Loretta Nastopuil, Georg Hess
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 AM
Duration 15mins Hall A8
Venetoclax in Patients With Chronic Lymphocytic Leukemia With 17p Deletion: 6-Year Follow-Up and Genomic Analyses in a Pivotal Phase 2 Trial
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF
Haematology - Oncology | Chronic Lymphocytic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Hall A8
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study
Al-Sawaf O, Zhang C, Robrecht S, Kotak A, Chang N, Fink A-M, Tausch E, Schneider C, Ritgen M, Kreuzer K-A, Chyla B, Eichhorst B, Jiang Y, Stilgenbauer S, Hallek M, Fischer K
Haematology - Oncology | Chronic Lymphocytic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:45 AM
Duration 5mins Vienna, Austria / Virtual (Hybrid)
Roche-Sponsored PNH & SCD Symposium at EHA 2022: Advancing C5 Inhibitor Therapy: Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease Showfile
Tahla Munir, Pablo Bartolucci
Haematology | Paroxysmal Nocturnal Hemoglobinuria - Sickle Cell Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.